Nuveen Asset Management, LLC Oric Pharmaceuticals, Inc. Transaction History

Nuveen Asset Management, LLC

$329 Billion
Q1 2024

A detailed history of Nuveen Asset Management, LLC transactions in Oric Pharmaceuticals, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 135,787 shares of ORIC stock, worth $1.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

135,787

Previous 135,787 -0.0%

Holding current value

$1.02 Million

Previous $1.25 Million 49.48%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$5.41 - $9.43 $179,785 - $313,377	-33,232 Reduced 19.66%	135,787 $1.25 Million
Q2 2023 Aug 14, 2023	BUY	$4.95 - $8.4 $836,644 - $1.42 Million	169,019 New	169,019 $1.31 Million
Q2 2022 Aug 15, 2022	SELL	$2.7 - $7.07 $304,419 - $797,128	-112,748 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$4.54 - $16.1 $7,214 - $25,582	1,589 Added 1.43%	112,748 $753,000
Q4 2021 Feb 14, 2022	SELL	$12.01 - $20.3 $96,776 - $163,577	-8,058 Reduced 6.76%	111,159 $1.31 Million

Q3 2021 Nov 12, 2021	BUY	$15.9 - $25.22 $63,902 - $101,359	4,019 Added 3.49%	119,217 $3.01 Million
Q2 2021 Aug 16, 2021	BUY	$17.37 - $25.34 $729,540 - $1.06 Million	42,000 Added 57.38%	115,198 $2.04 Million
Q1 2021 May 17, 2021	BUY	$23.67 - $36.85 $123,131 - $191,693	5,202 Added 7.65%	73,198 $1.79 Million
Q4 2020 Feb 16, 2021	BUY	$20.32 - $39.8 $693,968 - $1.36 Million	34,152 Added 100.91%	67,996 $2.3 Million
Q3 2020 Nov 16, 2020	BUY	$19.5 - $31.26 $2,944 - $4,720	151 Added 0.45%	33,844 $846,000
Q2 2020 Aug 14, 2020	BUY	$25.68 - $38.12 $865,236 - $1.28 Million	33,693 New	33,693 $1.14 Million

Others Institutions Holding ORIC

# of Institutions

113

Shares Held

59.3M

Call Options Held

302K

Put Options Held

7.7K

View Full List

About Oric Pharmaceuticals, Inc.

Ticker ORIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,576,700
Market Cap $298M
Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...

More about ORIC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account

Nuveen Asset Management, LLC Oric Pharmaceuticals, Inc. Transaction History